oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia
MRC, Ctr Neuromuscular Dis Newcastle, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England..
MRC, Ctr Neuromuscular Dis Newcastle, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England..
MRC, Ctr Neuromuscular Dis Newcastle, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England..
Show others and affiliations
2013 (English)In: Human Mutation, ISSN 1059-7794, E-ISSN 1098-1004, Vol. 34, no 11, 1449-1457 p.Article in journal (Refereed) Published
Abstract [en]

Duchenne muscular dystrophy (DMD) is an X-linked genetic disease, caused by the absence of the dystrophin protein. Although many novel therapies are under development for DMD, there is currently no cure and affected individuals are often confined to a wheelchair by their teens and die in their twenties/thirties. DMD is a rare disease (prevalence<5/10,000). Even the largest countries do not have enough affected patients to rigorously assess novel therapies, unravel genetic complexities, and determine patient outcomes. TREAT-NMD is a worldwide network for neuromuscular diseases that provides an infrastructure to support the delivery of promising new therapies for patients. The harmonized implementation of national and ultimately global patient registries has been central to the success of TREAT-NMD. For the DMD registries within TREAT-NMD, individual countries have chosen to collect patient information in the form of standardized patient registries to increase the overall patient population on which clinical outcomes and new technologies can be assessed. The registries comprise more than 13,500 patients from 31 different countries. Here, we describe how the TREAT-NMD national patient registries for DMD were established. We look at their continued growth and assess how successful they have been at fostering collaboration between academia, patient organizations, and industry.

Place, publisher, year, edition, pages
2013. Vol. 34, no 11, 1449-1457 p.
Keyword [en]
Duchenne muscular dystrophy, DMD, rare disease, disease registries, TREAT-NMD
National Category
Medical Genetics
Identifiers
URN: urn:nbn:se:oru:diva-56435DOI: 10.1002/humu.22390ISI: 000325426900001PubMedID: 23913485OAI: oai:DiVA.org:oru-56435DiVA: diva2:1082344
Available from: 2017-03-16 Created: 2017-03-16 Last updated: 2017-03-16Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Kimura, EnRoxburgh, RichardOliveira, JorgePosada, ManuelPalau, FrancescLindvall, BjörnMartin, Ann S.Flanigan, Kevin M.Gainotti, SabinaTaruscio, DomenicaKirschner, JanBeroud, Christophe
By organisation
Orebro University Hospital
In the same journal
Human Mutation
Medical Genetics

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 6 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf